Visualize HL7 Example and Test Instances (vi7eti)

Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/

Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.

BACK TO LIST

Patient
Name:	Smith, , Timothy,
DOB:	10-SEP-1941 (Age: 84)
Gender:	male
Address:	9 Jeffrey orchard NW1 North Joshuaville (United Kingdom)
ID:	8029-862360-6 (ECI)

Report
Date:	03-JAN-2022

Laboratory
dr Ample, Ex Laboratoire Central Européenne Boulevard du Jardin Botanique 32 1000 Brussels (Belgium)

Requested by
Evelina Children's Hospital SE1 7 London (United Kingdom)

Specimen
Collected:	03-JAN-2022

Hematology

Test	03-JAN-2022	Reference Range	Unit
Leukocytes [#/volume] in Blood by Automated count	8.9	3.6 - 10.5	10*3/uL
Erythrocytes [#/volume] in Blood by Automated count	5.0	4.3 - 6.1	10*6/uL
Hemoglobin [Mass/volume] in Blood	15.3	13.5 - 17.5	g/dL
Hematocrit [Volume Fraction] of Blood by Automated count	43.0	38 - 50	%
MCV [Entitic volume] by Automated count	90.8	76 - 98	fL
MCH [Entitic mass] by Automated count	30.5	27 - 33	pg
MCHC [Mass/volume] by Automated count	35.8	31 - 37	g/dL
Erythrocyte distribution width [Entitic volume] by Automated count	43.7	36.6 - 56.6	fL
Platelets [#/volume] in Blood by Automated count	238.6	155 - 415	10*3/uL
Platelet distribution width [Entitic volume] in Blood by Automated count	341.2 H	13.4 - 17.4	fL
Platelet mean volume [Entitic volume] in Blood by Automated count	11.0	7.4 - 12	fL

Chemistry

Test	03-JAN-2022	Reference Range	Unit
Hemoglobin A1c/Hemoglobin.total in Blood	5.5	4.5 - 6.4	%
Glucose [Mass/volume] in Blood	128.2	70 - 140	mg/dL
Urea nitrogen [Mass/volume] in Blood	19.5	7 - 25	mg/dL
Creatinine [Mass/volume] in Blood	0.7	0.6 - 1.3	mg/dL
Calcium [Mass/volume] in Blood	9.0	8.5 - 10.5	mg/dL
Sodium [Moles/volume] in Blood	144.0	135 - 145	mmol/L
Potassium [Moles/volume] in Blood	4.9	3.5 - 5.1	mmol/L
Chloride [Moles/volume] in Blood	109.5 H	98 - 107	mmol/L
Carbon dioxide, total [Moles/volume] in Blood	21.7 L	22 - 29	mmol/L
Cholesterol [Mass/volume] in Serum or Plasma	242.1 H	0 - 200	mg/dL
Triglyceride [Mass/volume] in Serum or Plasma	431.5 H	0 - 199	mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay	134.2 H	0 - 130	mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma	21.7 L	40 - 100	mg/dL
Microalbumin/Creatinine [Mass Ratio] in Urine	16.4	0 - 30	mg/g

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows significant dyslipidemia (high total cholesterol, LDL, triglycerides, and low HDL), which increases cardiovascular risk. There is mild hyperchloremia and low total CO₂, possibly indicating a mild metabolic acidosis. Glucose and renal function are within normal limits. Hematological parameters are unremarkable except for elevated platelet distribution width, which may suggest platelet activation or variability. Overall, the main concerns are lipid abnormalities and mild electrolyte/acid-base disturbances; clinical correlation and further evaluation are recommended.

Conclusion and Recommendations based on this report and previous findings known to us

The patient shows significant dyslipidemia (high total cholesterol, LDL, triglycerides, and low HDL), which increases cardiovascular risk. There is mild hyperchloremia and low total CO₂, possibly indicating a mild metabolic acidosis. Glucose and renal function are within normal limits. Hematological parameters are unremarkable except for elevated platelet distribution width, which may suggest platelet activation or variability. Overall, the main concerns are lipid abnormalities and mild electrolyte/acid-base disturbances; clinical correlation and further evaluation are recommended.